Indian pharma API and CRAMS firms see profit growth surge to 47% in Q1

Indian pharmaceutical API and CRAMS companies saw median profit growth surge to 47.1% in the June 2026 quarter, up sharply from 8% in March, according to a SOIC and StockScans report. The acceleration, based on 24 companies, was driven by commercialised CDMO projects, new capacity, and product launches. Operating profit growth hit 35.6%, while revenue rose 18.8%, with profitability outpacing sales. CDMO is a key growth driver, with Morepen Laboratories starting an ₹825-crore mandate and Aarti Pharmalabs guiding 40-50% growth. Capacity utilisation and emerging peptide and GLP-1 therapies also present opportunities.